The "Hub-and-Spoke" Model

BridgeBio operates differently than a traditional centralized pharmaceutical company. Its structure is designed for speed, scale, and risk diversification:

• The Spikes (Subsidiaries): Individual drug programs are housed in lean, autonomous subsidiary companies (affiliates). Each team is hyper-focused on a single disease or molecule, operating with the agility of a startup.
• The Hub (Central Services): BridgeBio provides a centralized "hub" of world-class expertise in regulatory affairs, clinical operations, manufacturing, and commercialization. This allows individual teams to draw on high-level resources without the overhead of a massive corporate bureaucracy.
• Asset-Level Focus: This model enables the company to rapidly reallocate capital. If a specific program fails to meet objective scientific criteria, it is shut down, and resources are immediately shifted to more promising candidates in the portfolio.

Commercial Products and Key Pipeline Programs

As of February 2026, BridgeBio has moved several therapies into the commercial market while maintaining one of the densest late-stage pipelines in the rare disease sector.

1. Marketed Medicines

• Attruby (acoramidis): The company's flagship product, approved in late 2024. It is a "near-complete" stabilizer of transthyretin (TTR) for the treatment of ATTR-CM (transthyretin amyloid cardiomyopathy). It has seen rapid global uptake in 2025 across the US, EU, and Japan due to its ability to significantly reduce cardiovascular-related hospitalizations.
• NULIBRY (fosdenopterin): The first FDA-approved therapy to reduce the risk of mortality in patients with Molybdenum Cofactor Deficiency (MoCD) Type A, an ultra-rare and life-threatening genetic disorder.

2. Late-Stage Clinical Pipeline

| Candidate | Target Indication | Status (2026) | | :--- | :--- | :--- | | Encaleret | ADH1 (Autosomal Dominant Hypocalcemia) | NDA submission planned for H1 2026; Potential first-in-class oral therapy. | | Infigratinib | Achondroplasia (Skeletal Dysplasia) | Phase 3 PROPEL 3 topline results expected by end of Q1 2026. | | BBP-418 | LGMD2I/R9 (Limb-Girdle Muscular Dystrophy) | NDA submission targeted for H1 2026 following positive Phase 3 interim data. | | BBP-812 | Canavan Disease | AAV9 gene therapy in a registrational trial; potential BLA filing by year-end 2026. |

Core Therapeutic Areas

BridgeBio focuses on Mendelian diseases (caused by a single gene mutation) where the underlying mechanism is well-understood:

• Cardiorenal: Addressing heart and kidney conditions driven by genetic factors, primarily focused on amyloidosis.
• Mendelian/Rare Disease: Targeting diverse conditions such as skeletal dysplasias (dwarfism) and metabolic disorders.
• Oncology: Through BridgeBio Oncology Therapeutics (BBOT), the company develops inhibitors for "undruggable" targets like KRAS and PI3Kα that drive specific cancers.
• Gene Therapy: Utilizing viral vectors to deliver functional copies of genes directly to patients with severe neurodegenerative conditions.

Strategic Significance

BridgeBio stands as a model for the "New Biotech." By maintaining a market capitalization of over $14 billion, it has proven that a diversified portfolio approach can overcome the high failure rates typical of the industry. The company is currently focused on its "Launch 3" initiative aiming to have three additional medicines (encaleret, infigratinib, and BBP-418) approved and launched globally by the end of the year.

Patient-First Philosophy: BridgeBio is known for its "Impatient for Patients" mantra, often partnering with academic institutions to ensure that early-stage research doesn't "sit on the shelf" but is instead aggressively moved into clinical testing.